Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.
| Website | http://entactbio.com |
| Employees | 20 (20 on RocketReach) |
| Phone | +1 617-674-5100 |
| Industry | Biotechnology Research |
| Keywords | Precision Medicine, Therapeutic Proteins, Novel Therapeutics, Small Molecule Drugs, Pharmaceutical Research, Therapeutic Agents, Drug Discovery, Drug Development, Biochemistry, Molecular Medicine, Target Identification, Chemical Biology, Biotechnology, Life Sciences, Biopharma |
| Competitors | Pfizer, GSK, AstraZeneca, Regeneron, Gilead Sciences, Moderna Therapeutics, Novavax, CureVac, INOVIO Pharmaceuticals, Inc., Sangamo Therapeutics, Inc. +46 more (view full list) |
Looking for a particular Entact Bio employee's phone or email?
Michael Gutch is the COO of Entact Bio.
20 people are employed at Entact Bio.
Entact Bio is based in Watertown, Massachusetts.